|
SERPINA3
|
Alzheimer's Disease
|
0.100 |
Biomarker |
BEFREE |
Protein-protein interaction (PPI) analysis revealed SERPINA3 and BDNF to possess high node degree interaction with literature derived candidate genes (LDGs) in AD males and females, respectively, thus were selected as potential AD targets.
|
31543038 |
2019 |
|
SERPINA3
|
Alzheimer's Disease
|
0.100 |
Biomarker |
BEFREE |
A total of 170 studies were included in the meta-analysis and systematic review, which demonstrated increased peripheral levels of high-sensitivity C reactive protein (Hedges's g 0.281, p<0.05), interleukin-6 (IL-6) (0.429, p<0.005), soluble tumour necrosis factor receptor 1 (sTNFR1) (0.763, p<0.05), soluble tumour necrosis factor receptor 2 (sTNFR2) (0.354, p<0.005), alpha1-antichymotrypsin (α1-ACT) (1.217, p<0.005), IL-1β (0.615, p<0.05) and soluble CD40 ligand (0.868, p<0.005), and CSF levels of IL-10 (0.434, p<0.05), monocyte chemoattractant protein-1 (MCP-1) (0.798, p<0.005), transforming growth factor-beta 1 (1.009, p<0.05), soluble triggering receptor expressed on myeloid cells2 (sTREM2) (0.587, p<0.001), YKL-40 (0.849, p<0.001), α1-ACT (0.638, p<0.001), nerve growth factor (5.475, p<0.005) and visinin-like protein-1 (VILIP-1) (0.677, p<0.005), in AD compared with the control.
|
30630955 |
2019 |
|
SERPINA3
|
Alzheimer's Disease
|
0.100 |
AlteredExpression |
BEFREE |
C-reactive protein (HR = 1.37 [1.05; 1.78]), interleukin-6 (HR = 1.40 [1.13; 1.73]), α1-antichymotrypsin (HR = 1.54 [1.14; 2.80]), lipoprotein-associated phospholipase A2 activity (HR = 1.40 [1.03; 1.90]), and fibrinogen were each associated with all-cause dementia, but neither was significantly associated with AD.
|
29605221 |
2018 |
|
SERPINA3
|
Alzheimer's Disease
|
0.100 |
Biomarker |
BEFREE |
Elevated peripheral interleukin (IL)-1β, IL-2, IL-6, IL-18, interferon-γ, homocysteine, high-sensitivity C reactive protein, C-X-C motif chemokine-10, epidermal growth factor, vascular cell adhesion molecule-1, tumour necrosis factor (TNF)-α converting enzyme, soluble TNF receptors 1 and 2, α1-antichymotrypsin and decreased IL-1 receptor antagonist and leptin were found in patients with AD compared with HC.
|
28794151 |
2017 |
|
SERPINA3
|
Alzheimer's Disease
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, ACT-17 variation presents a risk factor for AD in the worldwide population, especially in the Caucasian population.
|
22272609 |
2013 |
|
SERPINA3
|
Alzheimer's Disease
|
0.100 |
GeneticVariation |
BEFREE |
However, whether the genetic variants in the regulatory region (including the promoter and the two enhancers) of the ACT gene affect susceptibility to Alzheimer's disease (AD) remains controversial.
|
20378355 |
2010 |
|
SERPINA3
|
Alzheimer's Disease
|
0.100 |
GeneticVariation |
BEFREE |
We have investigated whether the -86 C/T promoter polymorphism in CHRNA7 gene, the signal peptide polymorphism of the alpha1-antichymotripsin (ACT) gene or the APOE genotype are associated with an increased risk of mild cognitive impairment (MCI) or affect the risk of evolution to Alzheimer's disease (AD).
|
18078695 |
2009 |
|
SERPINA3
|
Alzheimer's Disease
|
0.100 |
AlteredExpression |
BEFREE |
ACT levels were higher in AD patients than in CIND or controls.
|
18991685 |
2008 |
|
SERPINA3
|
Alzheimer's Disease
|
0.100 |
AlteredExpression |
BEFREE |
Higher CSF levels of neuroserpin and alpha(1)-antichymotrypsin were associated with the clinical diagnosis of Alzheimer disease (AD) and facilitated the diagnostic classification of AD vs controls.
|
17761554 |
2007 |
|
SERPINA3
|
Alzheimer's Disease
|
0.100 |
Biomarker |
BEFREE |
This result was further confirmed by the finding that addition of purified ACT induced the same Alzheimer's disease-related tau hyperphosphorylation in cortical neurons cultured in vitro.
|
16987932 |
2006 |
|
SERPINA3
|
Alzheimer's Disease
|
0.100 |
Biomarker |
BEFREE |
These data suggest that the ACT gene may affect AAO and disease duration of AD.
|
16137793 |
2006 |
|
SERPINA3
|
Alzheimer's Disease
|
0.100 |
Biomarker |
BEFREE |
The ACT gene appears to influence the early clinical development of the disease, and the interaction of the ACT and APOE genes affects clinical progression of AD.
|
15653173 |
2005 |
|
SERPINA3
|
Alzheimer's Disease
|
0.100 |
AlteredExpression |
BEFREE |
This effect is probably mediated by a higher binding affinity of the transcription initiation complex to the higher expressing allele and overexpression of ACT by astrocytes could thus contribute to increased beta-amyloid fibril formation in AD.
|
15530656 |
2004 |
|
SERPINA3
|
Alzheimer's Disease
|
0.100 |
Biomarker |
BEFREE |
In particular, polymorphisms within the ApoE and alpha1-ACT gene have been implicated in the aetiology of AD and s-IBM.
|
15159602 |
2004 |
|
SERPINA3
|
Alzheimer's Disease
|
0.100 |
AlteredExpression |
BEFREE |
ACT measurements in cerebrospinal fluid from an additional 34 AD cases and 16 controls showed elevated levels (p = 0.02) in AD.
|
12509851 |
2003 |
|
SERPINA3
|
Alzheimer's Disease
|
0.100 |
Biomarker |
BEFREE |
Our data extend previous reports regarding the inflammatory markers in the plasma and CSF of patients with AD and provide good evidence that levels of ACT, IL-6, MCP-1 and oxLDL in plasma and CSF might be candidates as biomarkers for monitoring the inflammatory process in AD.
|
12826739 |
2003 |
|
SERPINA3
|
Alzheimer's Disease
|
0.100 |
AlteredExpression |
BEFREE |
The ACT/codon -17 polymorphism showed significant association with ACT levels in male AD patients, while the effect of the intron 4 polymorphism was significant in both male and female patients.
|
11959399 |
2002 |
|
SERPINA3
|
Alzheimer's Disease
|
0.100 |
GeneticVariation |
BEFREE |
Main genes involved in AD include mutational loci (APP, PS1, PS2, TAU) and multiple susceptibility loci (APOE, A2M, AACT, LRP1, IL1A, TNF, ACE, BACE, BCHE, CST3, MTHFR, GSK3B, NOS) distributed across the human genome.
|
12369958 |
2002 |
|
SERPINA3
|
Alzheimer's Disease
|
0.100 |
GeneticVariation |
BEFREE |
The ACT codon -17*A allele was associated with increased risk of AD (OR for AA vs TT: 1.71; 95% CI: 1.16-2.53; P=0.007), especially in the presence of the APOE*4 allele (OR for AA vs TT: 2.35; 95% CI: 1.13-4.85; P=0.02).
|
11941486 |
2002 |
|
SERPINA3
|
Alzheimer's Disease
|
0.100 |
GeneticVariation |
BEFREE |
Apolipoprotein E and alpha-1-antichymotrypsin genotypes do not predict time to psychosis in Alzheimer's disease.
|
11936240 |
2002 |
|
SERPINA3
|
Alzheimer's Disease
|
0.100 |
AlteredExpression |
BEFREE |
Our data demonstrate that ACT promotes amyloid deposition and provide a specific mechanism by which inflammation and the subsequent upregulation of astrocytic ACT expression in AD brain contributes to AD pathogenesis.
|
11222634 |
2001 |
|
SERPINA3
|
Alzheimer's Disease
|
0.100 |
Biomarker |
BEFREE |
We discuss our findings in terms of a model in which cytokine-induced alpha(1)-antichymotrypsin synthesis in astrocytes constitutes a specific inflammatory pathway that accelerates the development of Alzheimer's disease and could at least partly underlie the regional specificity and species restriction of the neuropathology.
|
11578771 |
2001 |
|
SERPINA3
|
Alzheimer's Disease
|
0.100 |
Biomarker |
BEFREE |
Alpha1-antichymotrypsin (ACT: new identification SERPINA3) is a member of the serine proteinase inhibitor (serpin) gene family and biochemically has been shown to be a constituent of the senile plaques of Alzheimer's disease.
|
11702211 |
2001 |
|
SERPINA3
|
Alzheimer's Disease
|
0.100 |
GeneticVariation |
BEFREE |
Alpha-1-antichymotrypsin gene polymorphism and risk for sporadic Alzheimer's disease in a German population.
|
10559561 |
2000 |
|
SERPINA3
|
Alzheimer's Disease
|
0.100 |
AlteredExpression |
BEFREE |
Apolipoprotein E (APOE) genotypes did not independently affect blood ACT levels in both AD and controls; although, among AD patients, female AD patients with APOE 4,4 showed the highest level of serum ACT.
|
10629358 |
2000 |